Stockscreener 앱 받기
39.52
3.43%
1.31
Travere Therapeutics Inc 주식(TVTX)의 최신 뉴스
Why Travere Therapeutics (TVTX) stock is down today as insider sales hit the tape ahead of a key FDA date - ts2.tech
Travere Therapeutics (NASDAQ:TVTX) Stock Price Down 4% Following Insider Selling - MarketBeat
Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Shift From Loss To Profit - 富途牛牛
Travere Therapeutics Insider Sold Shares Worth $2,406,180, According to a Recent SEC Filing - marketscreener.com
Travere Therapeutics (NASDAQ:TVTX) Insider Peter Heerma Sells 4,980 Shares - MarketBeat
Inrig Jula, chief medical officer of Travere, sells $630,004 in TVTX - Investing.com Canada
Travere therapeutics (TVTX) SVP Calvin sells $296k in stock By Investing.com - Investing.com Canada
Travere therapeutics (TVTX) chief research officer sells $2.4m in stock - Investing.com Canada
Heerma, Travere therapeutics CCO, sells $199k in TVTX stock By Investing.com - Investing.com Canada
Insider Selling: Travere Therapeutics (NASDAQ:TVTX) CAO Sells 7,402 Shares of Stock - MarketBeat
Why Travere Therapeutics stock popped by nearly 14% on Wednesday - MSN
Travere Therapeutics Inc. (TVTX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Traders Buy Large Volume of Call Options on Travere Therapeutics (NASDAQ:TVTX) - MarketBeat
Travere Therapeutics (TVTX) Stock Watch: Pre‑Market Focus on the Jan. 13 FDA Decision After a 14% Rally - ts2.tech
Voya Investment Management LLC Acquires 27,133 Shares of Travere Therapeutics, Inc. $TVTX - MarketBeat
Is Travere Therapeutics Still Attractively Priced After Its 135% Share Price Surge? - Yahoo Finance
Why Travere Therapeutics (TVTX) Is Up 18.9% After FDA Eases FILSPARI Oversight And Delays Adcom - Yahoo Finance
Travere Therapeutics (TVTX): Valuation Check After FDA Tailwinds and FSGS Expansion Hopes for FILSPARI - Yahoo! Finance Canada
Travere Stock (+14%): FDA Catalyst Speculation Ignites Rally - Trefis
Why Travere Therapeutics Stock Popped by Nearly 14% on Wednesday - Finviz
Why Travere Therapeutics Stock Popped by Nearly 14% on Wednesday - The Motley Fool
Travere Therapeutics Inducement Grants: Market Anticipations - StocksToTrade
Is Travere Therapeutics Stock a Hidden Gem? - timothysykes.com
Travere Therapeutics stock gains as FDA messaging on proteinuria endpoint boosts Filspari approval hopes - Investing.com Australia
Travere Therapeutics (TVTX) Stock Jumps on Dec. 24, 2025: 52-Week High, FDA Catalyst Ahead, and Analyst Price Targets - ts2.tech
Travere Therapeutics (TVTX) Shares Surge Over 16% - GuruFocus
Travere Therapeutics (TVTX) Surges on Positive FDA Update - GuruFocus
Travere Therapeutics Expands with New Employee Stock Grants - timothysykes.com
Travere Therapeutics (TVTX) Sees a Significant 13.2% Surge - GuruFocus
Travere Therapeutics (NASDAQ:TVTX) Reaches New 52-Week HighHere's Why - MarketBeat
Travere Therapeutics stock hits 52-week high at 37.76 USD By Investing.com - Investing.com Nigeria
Travere Therapeutics stock hits 52-week high at 37.76 USD - Investing.com
Assenagon Asset Management S.A. Has $2.23 Million Stock Holdings in Travere Therapeutics, Inc. $TVTX - MarketBeat
Biotech Stocks Facing FDA Decision In January 2026 - RTTNews
The Technical Signals Behind (TVTX) That Institutions Follow - Stock Traders Daily
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Is Travere Therapeutics Inc. stock a safe buy before earningsJuly 2025 PreEarnings & Consistent Growth Stock Picks - Улправда
Is Travere Therapeutics Inc. stock a contrarian buyEarnings Trend Report & Fast Exit Strategy with Risk Control - Улправда
Can Travere Therapeutics Inc. stock double in next 5 yearsGlobal Markets & Verified Entry Point Detection - Улправда
Is Travere Therapeutics Inc stock a contrarian buy2025 Momentum Check & Community Trade Idea Sharing Platform - moha.gov.vn
Forecast Cut: How Travere Therapeutics Inc. stock trades during market volatility2025 Key Lessons & Real-Time Volume Spike Alerts - Улправда
How Travere Therapeutics Inc. stock reacts to Fed rate cutsStock Surge & Weekly Momentum Stock Picks - DonanımHaber
Will Travere Therapeutics Inc. stock maintain momentum in 2025July 2025 Pullbacks & Low Risk Investment Opportunities - DonanımHaber
Will Travere Therapeutics Inc. stock beat EPS estimates2025 Growth vs Value & Accurate Buy Signal Notifications - Улправда
How Travere Therapeutics Inc. stock trades during market volatility2025 Fundamental Recap & Daily Chart Pattern Signals - Улправда
Travere Therapeutics (TVTX) Gets a Buy from Evercore ISI - The Globe and Mail
Why Travere Therapeutics Inc. stock is seen as undervaluedMarket Volume Report & Capital Protection Trade Alerts - DonanımHaber
How Travere Therapeutics Inc. stock reacts to bond yieldsEntry Point & Reliable Intraday Trade Alerts - Улправда
IgA Nephropathy Market Dynamics Indicate Upward Trajectory Through 2034, Reports DelveInsight | Visterra, Chinook Therapeutics, Novartis, IgA proteases Selecta Biosciences, Shanghai Alebund Pharma - Barchart.com
FY2025 Earnings Estimate for TVTX Issued By HC Wainwright - MarketBeat
Insider Sell: Sandra Calvin Sells Shares of Travere Therapeutics Inc (TVTX) - GuruFocus
Travere Therapeutics Executive Sells Shares - TradingView — Track All Markets
VP Calvin Sells 2,910 ($104.8K) Of Travere Therapeutics Inc [TVTX] - TradingView — Track All Markets
Travere Therapeutics (TVTX) SVP sells 2,910 shares in Rule 10b5-1 trade - Stock Titan
Squarepoint Ops LLC Grows Position in Travere Therapeutics, Inc. $TVTX - MarketBeat
Travere Therapeutics, Inc. (NASDAQ:TVTX) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
0.57%
자본화:
|
볼륨(24시간):